Vision Loss News and Research

RSS

People suffering from vision loss are twice as likely to suffer from depression

People suffering from vision loss are twice as likely to suffer from depression as the general population. And many psychiatric medications can cause vision problems over time.

6 May 2014

Eye movement disorder increases as we age, study finds

Abnormal binocular vision, which involves the way eyes work together as a team, increases dramatically as we age, according to research from the University of Waterloo. The study also found a correlation between this condition, general health and antidepressant use.

2 May 2014

Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Australian and New Zealand patients suffering from vision impairment due to a type of diabetes-induced eye disease will have access to a new treatment, following a license deal between Australian biopharmaceutical company Specialised Therapeutics Australia and Alimera Sciences.

28 Apr 2014

Glaucoma drug may help reverse obesity-related vision loss in women

An inexpensive glaucoma drug, when added to a weight loss plan, can improve vision for women with a disorder called idiopathic intracranial hypertension (IIH), according to a study funded by the National Institutes of Health.

23 Apr 2014

Scientists examine Gpr109a receptor to find potential treatment for diabetic retinopathy

Like a daily pill to lower cholesterol can reduce heart attack and stroke risk, an easy-to-use agent that reduces eye inflammation could help save the vision of diabetics, scientists say.

22 Apr 2014

Discovery could have far-reaching implications for diagnosis and treatment of diabetic retinopathy

Indiana University researchers have detected new early-warning signs of the potential loss of sight associated with diabetes. This discovery could have far-reaching implications for the diagnosis and treatment of diabetic retinopathy, potentially impacting the care of over 25 million Americans.

17 Apr 2014

Researchers reveal why Peel has one of highest rates of diabetes in Ontario

According to researchers at St. Michael's Hospital, there are two significant reasons why Peel has one of the highest rates of diabetes in Ontario: neighbourhood design that discourages walking and a population with many residents whose ethnic backgrounds predispose them to diabetes.

11 Apr 2014

Occasional drinking and physically activity linked with reduced risk of developing visual impairment

A physically active lifestyle and occasional drinking are associated with a reduced risk of developing visual impairment, according to a study published online this month in Ophthalmology, the journal of the American Academy of Ophthalmology.

19 Mar 2014

Study: Just a fifth of people with hearing problems use hearing aid

Just a fifth of people with hearing problems wear a hearing aid, a study by The University of Manchester has found.

From The University of Manchester 18 Mar 2014

Research explores new diagnostic strategies to detect glaucoma

Research exploring several new diagnostic strategies to find the earliest changes in the eye to detect glaucoma is underway at the University of Alabama at Birmingham School of Optometry. One optometrist says awareness of this eye disorder is just as important as continuing to study it.

7 Mar 2014

Cataract surgery followed by use of contact lenses may be better solution for infants

For adults and children who undergo cataract surgery, implantation of an artificial lens is the standard of care. But a clinical trial suggests that for most infants, surgery followed by the use of contact lenses for several years—and an eventual lens implant—may be the better solution.

7 Mar 2014

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., has submitted an application for marketing authorization for EYLEA (aflibercept) Injection for the treatment of patients with diabetic macular edema (DME) to the Japanese Ministry of Health, Labour and Welfare.

3 Mar 2014

Study establishes innovative approaches to improve vision of young children with brain tumor

Robert Avery, DO, MSCE, of Children's National Health System and colleagues are establishing innovative approaches with technology and medication to improve the vision of young children who have visual pathway glioma, a type of brain tumor.

3 Mar 2014

Ophthotech reports net loss of $20.4 million for fourth quarter 2013

Ophthotech Corporation today announced financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on the Company's business and product development programs.

27 Feb 2014

UAB launches pilot program to detect earlier stages of glaucoma

Glaucoma is a silent disease. It does not hurt, symptoms are slow to develop, and most people do not notice any loss of vision until it is too late. A project by ophthalmologists at the University of Alabama at Birmingham will examine whether a partnership with community-based optometrists will improve detection and treatment of glaucoma, especially for high-risk populations.

27 Feb 2014

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).

26 Feb 2014

Ellex gets CE Mark approval for 2RT laser treatment of early stage AMD

Ellex Medical Lasers Limited, a pioneer in medical technologies for the diagnosis and treatment of eye disease, today announced that it has secured a CE Mark (Conformité Européenne) for its proprietary Retinal Rejuvenation Therapy (2RT) laser treatment of early Age-Related Macular Degeneration (AMD).

24 Feb 2014

Aerpio Therapeutics doses first patient in AKB-9778 Phase 2 trial for diabetic macular edema treatment

Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTPβ) that activates the Tie2 pathway to promote vascular stability, preventing abnormal blood vessel growth and vascular leak.

13 Feb 2014

Researchers examine link between gender and genetic disorder

A genetic disorder that affects about 1 in every 2,500 births can cause a bewildering array of clinical problems, including brain tumors, impaired vision, learning disabilities, behavioral problems, heart defects and bone deformities. The symptoms and their severity vary among patients affected by this condition, known as neurofibromatosis type 1 (NF1).

9 Feb 2014

Human visual system can retain plasticity even after extended blindness

Deprivation of vision during critical periods of childhood development has long been thought to result in irreversible vision loss.

28 Jan 2014